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Radiotherapy utilisationBackground and Purpose: Large non-age-specific radiotherapy utilisation rate (RTU) studies have demon-
strated that actual RTU is below the optimal recommended utilisation rate for both curative and palliative
intent radiotherapy indications. The optimal utilisation rate for the geriatric oncology cohort of patients
has not yet been determined. The purpose of this research was to examine the actual RTU for patients
treated in New South Wales (NSW), Australia as a function of increasing age, and the relationship
between RTU and tumour site, travelling distance and socio-economic status.
Materials & Methods: NSW Central Cancer Registry data (2009–2011) were linked to the NSW
Radiotherapy Dataset (2009–2012). RTU was calculated for patients aged <80 years and 80 years.
RTU was defined as the proportion of patients receiving at least a single course of radiotherapy within
12 months of a cancer diagnosis.
Results: 110,645 patients were diagnosed with cancer, of whom 27,721 received at least one course of
radiotherapy. The overall RTU was 25%. RTU for patients aged <80 years was 28% compared to 14% for
patients aged 80+ years (p < 0.001). On both univariate and multivariate analysis, increasing age, residen-
tial address in disadvantaged socioeconomic areas and increasing distance to the nearest radiotherapy
department were associated with a reduction in RTU.
Conclusion: Geriatric oncology patients are less likely to receive radiotherapy than their younger counter-
parts. Some of the reduction in RTU may be justifiable on the basis of limited life expectancy and co-
morbidity. Further research is required to determine the co-morbidity adjusted optimal RTU in older
patients.
 2020 Published by Elsevier B.V. on behalf of European Society for Radiotherapy & Oncology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The population of older people for whom cancer treatment
needs to be considered is increasing. This is in step with the ageing
population and therapeutic advances in oncologic management. In
Australia, it has been estimated that approximately 50% of people
aged 65 years and above will develop cancer [1], and the overall
proportion of people with cancer in this age group is projected to
increase from 10-13% (1982–2007) to 17% by 2020 [2]. For patientsaged 80–84 years, the number of new cases is projected to increase
from 7570 to 9870 for males, and 5030 to 6120 for females, from
2011 to 2020 [2]. Worldwide, it is predicted that the proportion
of cancer patients aged 65 years and above will increase from
47.5% (6.7 million patients) in 2012 to 60% (14 million patients)
in 2035 [3]. However, there is under-representation of the geriatric
(80 years) cohort in clinical trials, thus a need for further studies
to examine and inform their care [4,5].
Radiotherapy is an important treatment option for older people
with cancer. However, limited data are available on current and
optimal radiotherapy utilisation (RTU) for older patients. Large,
non-age specific RTU studies have demonstrated that actual RTU
is below optimal utilisation for both curative and palliative intent
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to occur in all major tumour sites, including lung, breast, rectal
and prostate cancer. There is evidence that an inappropriate reduc-
tion in RTU (non-treatment where evidence suggests benefit)
results in decreased local control and overall survival [8–11]. The
factors contributing to the reduction in RTU in older cancer
patients have not yet been examined.
Improvements in radiotherapy technique are associated with a
reduction in side effects [12]. Anecdotally, it is thought that older
patients are generally ‘fitter’ in the current compared to previous
eras. Furthermore, the disability-adjusted life year or DALY has
reduced in patients aged 80+ years as reported in the Australian
Bureau of Statistics disease burden and mortality estimates [13].
This is supported by the literature showing a reduction in func-
tional disabilities in the modern era despite the number of medical
co-morbidities increasing with advancing age [14]. Therefore, it is
possible that a greater proportion of older patients may benefit
from radiotherapy than predicted based on historical experience.
The objectives of this study were to analyse the factors that con-
tribute to a reduction in RTU for people <80 and 80 years of age.Table 1









<60 33 088 9726 29.4 %
60–69 29 706 8271 27.8 %
70–79 26 868 6 812 25.4 %
80–89 17 955 2 679 14.9 %
90+ 3 028 233 7.7 %
Total 110 645 27 721 25.1 %
<80 years 89 662 24 809 27.7%
80+ 20 983 2 912 13.9%Materials and methods
All patients diagnosed with a notifiable cancer in New South
Wales (NSW), Australia, from 2009-2011 were included in the
study. NSW Central Cancer Registry data for this period were
linked to the NSW Radiotherapy Dataset for 2009–2012. The
NSW Central Cancer Registry includes all cancers except for non-
melanomatous skin cancers. The radiotherapy dataset includes all
patients treated in both the public and private sector. Performance
status information was not available.
For the purpose of this research, the geriatric oncology patient
group of interest was defined as those 80 years of age. In the geri-
atric oncology literature, the specific cut-off age is described vari-
ably. The International Society of Geriatric Oncology (SIOG) [15–
18] uses 70 years and above. However, clinical treatment para-
digms for radiotherapy often change when patients are 80 years
of age, when the associated life expectancy is <10 years [19].
Therefore the 80 age group was considered of particular interest.
Age was categorised into five age groups: <60, 60–69, 70–79, 80–
89 and 90+ years.
The actual RTU was calculated by dividing the number of
patients who received at least one course of radiotherapy within
12 months of diagnosis by the total number of cases of cancer in
a particular population. This methodology has been reported previ-
ously [20,21]. The four most common primary cancer sites, breast,
prostate, lung and rectal, were chosen to best reflect daily clinical
practice, with the International Classification of Diseases, tenth
revision (ICD-10) codes of C50, C61, C34 and C20 respectively.
RTU rates were compared by age group, primary site, distance to
the nearest radiotherapy department and socioeconomic status.
Residential postcodes were classified using the census-based
Socio-Economic Index for Area (SEIFA) categories based on the
Index of Relative Socio-economic Disadvantage (IRSD) [22,23]. Dis-
tance to nearest radiotherapy department was examined as both a
continuous and categorical variable; a cut-point of 100 km was
chosen based on previous research that we have reported [21].
Descriptive statistics were carried out using the Chi-square test
or Fisher’s exact test for categorical variables. Univariate and mul-
tivariate logistic regression analyses were performed to examine
the association of RTU with age after taking into account primary
site, stage, degree of spread, sex, distance to the nearest radiother-
apy department, remoteness and socioeconomic status [22]. Multi-
collinearity between geographic variables was assessed.18SPSS (SPSS Version 25. Armonk, NY: IBM Corp.), SAS version 9.4
(SAS Institute Inc., Cary, NC, USA) and ArcGIS (ESRI 2018. ArcGIS
Desktop: Release 10.5 Redlands, CA, USA) were used in statistical
analysis. P values < 0.05 were considered statistically significant.Ethics
Ethics approvals were obtained from all relevant institutional
and registry Human Research Ethics Committees.Results
RTU and age
Overall, radiotherapy utilisation decreased with increasing
patient age (Table 1). RTU for patients aged less than 80 years
was 28% compared to 14% for patients aged 80 years and above
(p < 0.001). In patients aged 70–79 years, the RTU was 25%. The
drop off in RTU was most marked from the 80+ year age group.RTU and tumour site
Radiotherapy utilisation decreased with increasing age from
60 years for all major tumour sites, except for patients with pros-
tate cancer where the peak RTU (35.8%) was observed in the 70–
79 year age group and declined thereafter (Fig. 1).RTU and distance to the nearest radiotherapy department
Fig. 2 shows that for patients residing more than 100 km from
the nearest radiotherapy department, patients aged 80 years and
above were less likely to receive radiotherapy than younger
patients (p < 0.001). The correlation was similar for all individual
tumour sites.RTU and socio-economic status (IRSD)
RTU was lowest for patients living in residential areas with the
lowest socioeconomic status (Table 2). This effect was consistent
for patients aged <80 years and patients aged 80+ years. For exam-
ple, in patients with breast cancer aged 80 years, RTU was 29.6%
in the least disadvantaged areas (IRSD-5), compared to 22.8% in the
most disadvantaged areas (IRSD-1) (p < 0.001). For breast cancer
patients younger than 80 years of age, RTU was 68.2% in the least
disadvantaged area (IRSD-5) compared to 64.2% in the most disad-
vantaged areas (IRSD-1) (p = 0.001). There was no statistically sig-
nificant interaction between socioeconomic status and age group
on RTU (p = 0.38).
Fig. 1. Radiotherapy utilisation rates by tumour site and patient age.
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Fig. 2. Radiotherapy utilisation(RTU) rates by tumour site, patient age and distance to the nearest radiotherapy department.
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For all cancers combined, univariate analyses showed age,
socioeconomic status and distance were associated with a reduc-
tion in RTU (Table 3). All factors significant on univariate analysis
were included in the multivariate analysis (Table 4). The multivari-
ate analysis demonstrated that increasing age, residence in areas of
socioeconomic disadvantage and increasing distance to the nearest
radiotherapy department were significantly associated with a
reduction in RTU.19Discussion
Our Australian population-based research demonstrated a
decrease in radiotherapy utilisation with increasing age across all
tumour sites except prostate cancer, and with increasing distance
to the nearest radiotherapy department. There was a decrease in
RTU in older patients from lower compared to higher socioeco-
nomic areas. On univariate and multivariate analysis, increasing
age, lower socioeconomic status and greater distance and remote-
ness were all significantly associated with lower RTU. Our results
Table 2
Radiotherapy utilisation rates by tumour site patient age and Index of Relative Socioeconomic Disadvantage (IRSD).
Tumour site IRSD* Number of patients <80 years 80 + years p value
Lung IRSD-1 2 369 42.0% 23.2% <0.001
IRSD-5 1 427 47.7% 27.6% <0.001
Breast IRSD-1 2 322 64.2% 22.8% <0.001
IRSD-5 3 088 68.2% 29.6% <0.001
Rectal IRSD-1 784 41.5% 23.9% <0.001
IRSD-5 576 29.6% 22.7% 0.17
Prostate IRSD-1 3 676 27.0% 12.8% <0.001
IRSD-5 4 331 18.9% 17.7% 0.52
Other IRSD-1 12 887 16.4% 9.6% <0.001
IRSD-5 12 430 16.0% 10.8% <0.001
* IRSD-1 (most disadvantaged) IRSD-5 (least disadvantaged).
Table 3
Univariate analysis of factors affecting RTU.
Variable No. of patients P-value Odds ratio 95% C.I. for Odds ratio
Lower Upper
Age - continuous 110,645 <0.001 0.986 0.985 0.987
Age - group .
< 45 years 9,145 <0.001 2.265 2.132 2.406
45–59 years 23,943 <0.001 2.714 2.587 2.847
60–69 years 29,706 <0.001 2.396 2.287 2.510
70–79 years 26,868 <0.001 2.109 2.011 2.213
80 + years 20,983 1.000
Sex
Males 62,641 1.000
Females 48,004 <0.001 1.496 1.456 1.538
Degree of spread
Localised disease 45,429 1.000
Regional disease 23,550 <0.001 2.323 2.244 2.404
Distant disease 17,576 <0.001 1.695 1.630 1.762
Indeterminate 24,090 <0.001 0.643 0.616 0.671
Country of birth
Australian born 45,590 1.000
Overseas born 21,404 <0.001 1.106 1.067 1.147
Unknown or missing 43,651 <0.001 0.754 0.731 0.777
Socio-economic status (IRSD)
IRSD-1 Most disadvantaged 22,038 1.000
IRSD-2 22,334 0.306 0.978 0.936 1.021
IRSD-3 22,017 0.119 1.035 0.991 1.081
IRSD-4 22,172 0.001 1.078 1.033 1.125
IRSD-5 Least disadvantaged 21,852 0.854 0.996 0.954 1.040
Residential remoteness
Major cities 78,191 1.000
Inner regional 24,782 <0.001 0.831 0.803 0.859
Outer regional 7,061 <0.001 0.767 0.723 0.814
Remote & very remote 597 0.264 0.898 0.744 1.084
Residential distance from radiotherapy – continuous 110,624 <0.001 0.998 0.998 0.999
Residential distance from radiotherapy – group
<100 km 100,031 1.000
100 km 10,593 <0.001 0.765 0.728 0.803
IRSD, Index of Relative Socio-economic Disadvantage.
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tion studies as outlined below [11,31,32,35,36]. Although there
has been increasing interest in the medical literature regarding
geriatric oncology, reports of age-specific RTU are limited.
In the NSW 45 and Up Study, a reduction in RTU was noted in
patients 80+ years of age, although age-specific RTU details were
not the subject of this research [24]. The 45 and Up study was a
population cohort study which utilised a questionnaire adminis-
tered in 2006–2009 to 267 153 patients aged from 45 years. This
dataset was linked to the NSW Cancer Registry and other health
databases. 3667 patients were aged 80+ years in this paper (21%)
and 18% received radiotherapy (vs 33.8 % in the 60–69 year group).
However, there is evidence that the 45 and Up cohort are healthier
on average than the general population [25,26].20There is a potential for worsening general medical health and
thus suitability and safety for receiving radiotherapy with advanc-
ing age. Guidelines have been published by the International Soci-
ety of Geriatric Oncology (SIOG) on all the major tumour sites
including breast, lung, rectal and prostate to guide management
for geriatric patients [15–18]. These documents aim to support
clinical decision making by increasing knowledge on geriatric
oncology. The SIOG guidelines advise treatment recommendations
based on a patient’s medical co-morbidities and frailty rather than
chronological age per se. For example, the breast cancer guidelines
state that ‘Age alone should not dictate any aspect of management of
older individuals with breast cancer. All decisions should consider
physiological age, estimated life expectancy, risks, benefits, treatment
tolerance, patient preference and potential treatment barriers [15].’
Table 4
Multivariate analysis of factors affecting RTU.
Variable No. of patients P-value Odds ratio 95% C.I. for Odds ratio
Lower Upper
Age -continuous 110,645 <0.001 0.986 0.985 0.987
Sex
Males 62,641 1.000
Females 48,004 <0.001 1.331 1.294 1.369
Degree of Spread
Local disease 45,429 1.000
Regional disease 23,550 <0.001 2.276 2.198 2.357
Metastatic disease 17,576 <0.001 1.755 1.686 1.827
Indeterminate 24,090 <0.001 0.695 0.665 0.725
Country of birth
Australian born 45,590 1.000
Overseas born 21,404 0.031 1.043 1.004 1.083
Unknown or missing 43,651 <0.001 0.761 0.737 0.786
Socio-economic status
IRSD-1 (most disadvantaged) 22,038 1.000
IRSD-2 22,334 0.895 0.997 0.953 1.043
IRSD-3 22,017 0.811 1.006 0.961 1.052
IRSD-4 22,172 0.816 1.005 0.960 1.053
IRSD-5 (least disadvantaged) 21,852 <0.001 0.912 0.870 0.956
Residential remoteness
Major cities 78,191 1.000
Inner regional 24,782 0.011 0.947 0.908 0.988
Outer regional 7,061 0.379 1.039 0.954 1.132
Remote and very remote 597 <0.001 1.736 1.361 2.215
Residential distance from radiotherapy - continuous 110,624 <0.001 0.998 0.998 0.999
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ment and scores should be used and there is likely to be high vari-
ability in fitness assessment.
Various performance scores may be used to assist in patient
selection for treatment. The ECOG performance score, introduced
in the 19600s, is well-established; assessing patient’s function
and independence and thus suitability of treatment [27]. Unfortu-
nately, there is incomplete recording of patients’ ECOG perfor-
mance status in our dataset. Other methods may be used to
assess functional status [28–30]. The multiple scoring systems
highlight the importance of performance status and co-
morbidities in treatment decision making, but also the difficulty
in attaining consensus criteria to help guide management and then
train oncologists in their application, and no attempts to routinely
collect these data.
In our research, a reduction in RTU was noted across different
tumour sites. The following tumour-site specific articles in the lit-
erature also report a reduction in RTU across different tumour
sites. Vinod et al., demonstrated a reduction in lung radiotherapy
utilisation with increasing age, even in patients of good perfor-
mance status (ECOG 0-2) [31]. McAleese et al. reported that the
elderly, defined as age 70 years, were less likely to receive
guideline-recommended curative intent treatment for non-small
cell lung cancer compared to younger patients (40% vs. 60%) [32].
More recently, with advances in treatment techniques and greater
access to specialised including stereotactic radiotherapy treat-
ments, there is evidence of increased radiotherapy utilisation in
elderly lung cancer patients, with utilisation increasing from 26%
to 42% from 1999-01 to 2005–07 [33] as more elderly patients
are offered curative radiotherapy as an alternative to surgery. Vide-
tic et al. reported on their single institution experience of stereo-
tactic radiotherapy in patients with lung cancer 90 years of age
or older and concluded that radiotherapy is safe and effective in
this age group [34].
The current literature also demonstrates a decrease in RTU for
breast cancer with increasing age. Struikmans et al. reported a
reduction in radiotherapy utilisation following breast-conserving
surgery with increasing patient age, particularly in patients aged
are 75 years, finding an odds ratio of 0.13 for this patient group21versus patients less than or equal to 50 years of age [11]. Showalter
et al. on examining the SEER database, demonstrated a reduction
for adjuvant radiotherapy in stage I breast cancer patients 80 years
of age and above following breast-conserving surgery, with a RTU
of 6.4% [35].
Radiotherapy utilisation is reduced with increasing age in rectal
cancer patients. Jobson et al. demonstrated, in a population-based
study in the Netherlands 1997–2008, that pre-operative radiother-
apy decreased to 17%-26% for patients aged 85–89 years compared
with 47–69% in patients aged 60–64-years [36].
There is less data available in the literature on radiotherapy
benefits for older patients with prostate cancer. Of note, the SIOG
Task Force stated that if patients are elderly but fit, standard treat-
ment is recommended [16]. Prostate RTU increased up until age 80
contrary to the findings for other cancers, perhaps because surgery
is offered or accepted less frequently in prostate cancer patients
with advancing age and low fitness. For the other major tumour
sites, the radiotherapy offered is more frequently adjuvant therapy,
and appears to be considered less important with increasing age.
For some tumour sites such as breast cancer, this may be entirely
appropriate when other competing adjuvant therapies may ade-
quately reduce recurrence risk (such as early, ER-positive breast
cancer being managed with adjuvant endocrine therapy in prefer-
ence to radiotherapy) [37]. However, for other tumour sites, such
as rectal cancer, this reduction in radiotherapy utilisation may or
may not be appropriate depending on the predicted patient prog-
nosis and their locoregional recurrence risk.
With regards to place of residence and distance to the nearest
radiotherapy department, our results are similar to an earlier
NSW study using a 2004–2006 dataset [21]. With an increase in
the number of regional centres in recent years, it is expected that
RTU may increase [7].
The duration of treatment, and the provision of shorter or
‘hypo-fractionated’ courses of radiotherapy may also increase the
RTU in the older cohort of patients, with less treatment atten-
dances required. Of note, certain hypo-fractionated radiotherapy
schedules for specific cancer sites are considered standard of care
for patients of all ages, for example, the breast cancer hypo-
fractionated regimens [38,39].
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cancer outcomes and may also correlate with the presence of co-
morbidities. Galvin et al. in their systematic review, demonstrated
that low socioeconomic status and advancing age were associated
with poorer cancer specific and overall survival [40]. There are lim-
ited data on the relationship between socioeconomic status and
RTU in older patients. Hui et al. reported on the socioeconomic sta-
tus and patterns of care in NSW patients with lung cancer and
found no difference in RTU rates based on IRSD categories [41].
However, less than 12% of patients were aged 70 years and above
in this older study (with the patient population from January
1996-December 1996).
A concern by treating and referring clinicians may be the toler-
ance of radiotherapy toxicity in the elderly cohort of patients.
There is research showing older patients can be safely treated with
radiotherapy. A French multicentre retrospective study showed
that radiotherapy was safe in patients 90 years of age or older
[42]. This age group was reported to represent approximately 1%
of patients treated in their centres. Kocik et al., reported that 41%
of patients aged 90 years and above evaluated at their Austrian
Cancer Centre (2005–2016) received definitive radiotherapy in
their retrospective study [43], and 90% of these patients completed
their course of treatment. The modern radiotherapy treatment
techniques are also associated with a reduction in side effects, with
an increase in the precision and accuracy of treatment [44].
Whilst appropriate treatment decisions are essential and
expected, it is also important to note that if radiotherapy is withheld,
the prognosis may be worse. The inferior clinical outcomes associ-
ated with the underutilisation of radiotherapy have been previously
reported. In a younger cohort, of patients, there is a reduction in local
control and survival if RT is not administered [20,45]. Hanna et al.
reported that RT is associated with a 5-year improvement in local
control in 10.4% and 5-year overall survival benefit in 2.4% in all
patients [45]. The appropriate utilisation of radiotherapy is also
potentially more important in geriatric patients if other treatment
options, such as surgery and systemic therapies, are limited. Research
exploring this topic is unfortunately limited.
The strengths of this research were the population-based study
design, and the large number of cases. To our understanding, this is
the first time that geriatric oncology RTU across multiple cancer
sites using a large cancer registry has been reported in the litera-
ture. The limitations were the lack of ECOG performance status
data and thus ability to determine the appropriate RTU in this
cohort of patients. Other relevant data that were not present in this
database include receipt of surgery, chemotherapy or targeted
therapy, patient preference and caregiver availability.Conclusion
Radiotherapy utilisation rates decreased with increasing age
except for prostate cancer. This reduction in RTU rates occurs
across the major tumour sites, in patients of lower socio-
economic status and with increasing distance from radiotherapy
departments. Further research is required to estimate the appro-
priate proportion of geriatric patients who should receive radio-
therapy and to examine reasons for any gap. The development of
a co-morbidity/frailty adjusted score for optimal radiotherapy util-
isation rate would assist in clinical decision making, especially in
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